GWS
TVTX icon

Glassman Wealth Services’s Travere Therapeutics TVTX Stock Holding History

Glassman Wealth Services’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22
Closed – – 1578
2019
Q4 		$0 Buy
+22
New +$281 ﹤0.01% 1491

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Glassman Wealth Services's TVTX Position: Q1 2020 in Review

Glassman Wealth Services sold out of Travere Therapeutics (TVTX) in Q1 2020, closing a stake of 22 shares.

Glassman Wealth Services first reported a position in TVTX in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 124 funds tracked by Wall St. Rank hold TVTX as of Q1 2020.

  • Glassman Wealth Services reported no remaining Travere Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Glassman Wealth Services sold 22 Travere Therapeutics shares in Q1 2020.
  • Glassman Wealth Services first reported a position in Travere Therapeutics in Q4 2019 and held it in 1 quarter.
  • Glassman Wealth Services's Travere Therapeutics position peaked at $0 in Q4 2019.
  • 124 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2020.

Based on Glassman Wealth Services's 13F filing for Q1 2020, filed 12 May 2020.